Advertisement
Research Article

SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis

  • Robert T. Jacobs mail,

    bob.jacobs@scynexis.com

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Bakela Nare,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Stephen A. Wring,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Matthew D. Orr,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Daitao Chen,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Jessica M. Sligar,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Matthew X. Jenks,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Robert A. Noe,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Tana S. Bowling,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Luke T. Mercer,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Cindy Rewerts,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Eric Gaukel,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Jennifer Owens,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Robin Parham,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Ryan Randolph,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Beth Beaudet,

    Affiliation: SCYNEXIS, Inc., Research Triangle Park, North Carolina, United States of America

    X
  • Cyrus J. Bacchi,

    Affiliation: Haskins Laboratory, Pace University, New York, New York, United States of America

    X
  • Nigel Yarlett,

    Affiliation: Haskins Laboratory, Pace University, New York, New York, United States of America

    X
  • Jacob J. Plattner,

    Affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, United States of America

    X
  • Yvonne Freund,

    Affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, United States of America

    X
  • Charles Ding,

    Affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, United States of America

    X
  • Tsutomu Akama,

    Affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, United States of America

    X
  • Y.-K. Zhang,

    Affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, United States of America

    X
  • Reto Brun,

    Affiliation: Swiss Tropical and Public Health Institute, Basel, Switzerland

    X
  • Marcel Kaiser,

    Affiliation: Swiss Tropical and Public Health Institute, Basel, Switzerland

    X
  • Ivan Scandale,

    Affiliation: Drugs for Neglected Diseases initiative, Geneva, Switzerland

    X
  • Robert Don

    Affiliation: Drugs for Neglected Diseases initiative, Geneva, Switzerland

    X
  • Published: June 28, 2011
  • DOI: 10.1371/journal.pntd.0001151

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.